 Giuseppe Conti je prezident v Netvala asocijnosti, ko je vsega asocijnosti technologičnih transferofisov v prinspečnih in publiki resečnih organizacijov v Italii. In tukaj smo tukaj tukaj v Favio Terrandi, da se vse vse nekaj. So Giuseppe, please give you your summarization of the different lessons we will learn today. So thank you very much for having me here, having us here, let me say, and thanks for the organizers, for making possible this kind of event, amazing and inspiring event. So thanks to Fabio, to Marica, to Valeria, all people involved in organizing that. Thank you very much. And so my duties try to get some conclusions. Actually it's quite a difficult task due to such amazing talks and so inspiring talks. So I'm going to try to emphasize highlights, let me say, collected in these two days, jumping among some keywords. Apologize to Lucia for not including her key messages due to lack of time, because it's like a real time conclusions. OK. We started with Fabio for his introduction to emphasize the value of technology transfer and to stress the aim is to add to the growth of technology transfer in Italy and promote the innovative process in focusing on IP management and will listen IP management several times and new center of TT is coming. So I make some suspense for the next talk. Then Ricardo tried to make a sort of definition of technology transfer and is the capability to understand, select, extract, translate, like Lucia told us, address research results in order to generate new knowledge impact and progress. And TT requires time, cost, investment and risk. And these are, I think, the main key messages. Prof. Aldini described the path, the long journey. We heard about the long journey several times. And he described within the business development phase actually three different models. Different because you can deal with pharmaceutical companies, so big pharma, but also with biotec companies and the starter companies. And he showed us pro and cons that you have to take into consideration. And then Ian made the first conclusion of the first day. I took actually several notes. I tried to summarize because he talked about the fun. So it's also a funny activity. And he stressed the importance of making experiences and actually also Lucia told us the same thing, to try and make experiences and not to be afraid of the failure. And then he moved to quite interesting question. How difficult it is to have good TTO professionals supporting researchers? How difficult? Because they need to understand the science. Like once again Lucia told us. And to understand the value of IP, to know the market, to build trust and to have patience. So indeed it's not an easy job. Then today Maria Grazia talked to us about the translational research that can bridge the gap between academia and the industry. So focused on that way. She talked about the balance or unbalance between regulatory and commercial risk, once again risk, that are higher, higher than scientific risk. And this is not obvious probably. And then they find the role in some way of a human technical, trying to answer to Fabio question, can be strategically fundamental in order to build a system that is moved by a common goal, actually an ecosystem of both infrastructures and all different stakeholders from academia, industry and investors. That can be the main key factors. Alessandro gave us an inspirational talk, really inspirational talk. It started from the issue that there is more money than good ideas. We can think about it. Also he told us about the fact that investors can help you to find a killer market application, which is quoted Alessandro on the same issue. And you have to accept the fact of changing your technology to create a product. It's another step, different step. He gave us a quite romantic picture on free balances between falling in love and love actually, risk and specialization, failure and success. And I like the fact that you want to be an entrepreneur, you must consider these two words, not like opposite, so failure and success. And life is too long for being always the same. I like also very much. Anja gave us a technical speech of course because it's important to also address attention to technical things. I like to underline that IP sometimes is looking at a problem. Indeed, she gave us a speech that the pattern can be the balanced solution with different interests and I think it's quite interesting. Of course, you have to look at the requirements to be satisfied, but also if there is a market because patterns are costly. And so you have to consider in advance as early as possible the need and the market. And keep in mind to pattern before to publish of course. Once again. Ana Maria stressed the method, a model. She gave us some example about using some tools like proof of concept that are quite also in Italy. We started to use this kind of tools both in the public and the private way. And once again she told us that TT is not a one shot activity. So once again is a long journey. So to get to the conclusion, TT is difficult. But we heard about the fact that there is more money than ideas. So ok, we can try to catch it. To take care of the problem and not fall in love into the solution. Of course to protect your IP. So there is the technical part to be considered. To listen to the need once again before thinking at an IP. So try to design the IP, listen to the need and to look at the impact. So to the commercial part, the industry and to the investors. So TT is difficult but can be simple with practice, practice and practice. So Fabio. We in this couple of days heard a lot of interesting experiences and inspirational stories. But we shouldn't forget that in Italy we have a very good science. In particular in life science and not only but in life science. And in Milan there is an incredible concentration of institution of research and hospitals that probably in no other places in Europe have the same density. I don't know if I'm wrong. We are one of the best around the world and for sure in Italy. We shouldn't forget on the other side that even we heard very nice stories that we are very weak on technology transfer and the devalorization of science. We are here all struggling since many years but it's not enough I would say. Because if we compare the results in science and the results we have in technology transfer and in creating IPs and new companies in the field we shouldn't be satisfied at all. We must do better. And this is what I would like to give as a message to everyone that is here and all the people who is following us online we should cooperate as far as possible, collaborate, talk and strengthen one each other. We should avoid the Italian bad attitude to fight one each other because this is our main character. And should remember that we are very weak if we compare two countries where they are more or less the same level of science production. This morning we heard about the numbers of the Stanford University or the number of the MIT and the Boston areas. They are astonishing if we compare to the numbers that we have. Even if we did a lot of work and there has been incredible successes if we get back to 30 years ago. So what I would like to do is to give this message Human Technopol has received a mission to give a contribution in the field of technology transfer tool. I would like to have such a contribution in the more open way to collaborate, to talk to do something together. So I would like to give all the speakers and all the listeners at home the message that we want to hear messages from you about what to do together and how to reinforce this platform because I would like to build up a platform that could be helpful for the people working in this field. With a couple of main directions, I would say. First of all, of course we should take care of the growing research capacity of the Human Technopol. We heard that we now are more or less 250 people. At the end of 2023 there will be more or less 450 people. The final objective is to reach a thousand researchers. So it's an impressive amount of research capacity and there should be the capacity to valorize such a size. On the other side, we are talking with hospitals, with public institutions, with funds, with all the relevant institutions and ventures like the Teleton Foundation, how to promote a center that could be helpful for them, but also for all the researchers, all the young scientists that would like to be entrepreneurs and so on and so forth. So it's too early to give the exact outline of what will be the center and the outcome of such a work. What I can mention now is that this is the first initiative. It will be followed by a training activity we will do in collaboration with Netfal and use. I would like to do some work of communication of the experiences. Even the ones that we heard here and the one that we have been talked about, because another problem in Italy is that we do not know exactly how much we can do and we are not trusting ourselves, first of all. And we should reinforce our self-confidence because we can do it. And I hope that in the next few weeks we will start such a training activities that is open to everyone who is listening and we will ask you to apply for such an activity that will be free. And then we will organize together other initiatives such as communication, talk colloquia. And if possible, I would like to dialogue and criticize even the model we would like to propose for helping technology transfer activities in life science at national level and not only. That's it. This is my short message. I have to talk for 15 minutes because... No, we can have a talk with the present people here. I would like to introduce briefly for discussion surely with the speakers, but also if someone has some experience or some idea about one problem that is not underlined during these couple of days, unless someone asks something during the questions. That is the problem of the relationship that in Italy is particularly critical between public and private because it is true that Italian research is of very high quality, but it is also true that we have learned how to perform the different phases of technology transfer and we show you some Italian experiences of very high success. Why this is so local and so few cases? Because normally this is impeded by the regulation in this country because public research and the majority of research is public belong to the public bodies and public bodies refer to a sort of regulation that impedes particular relationship with private, with money, with profit. This is impeded. So we can teach, we can try, but if someone else says you cannot do this, you cannot do that, this is very, very, very high risk. So I like to ask, because human technology in particular this technology transfer experience that will start has been financed by public, they promote this and the first answer is okay, I want to promote, sit on the table and discuss which is the pigment, because unless, unless you should go to the court and defend because you try to treat money with others. So this is in our opinion, our opinion is one of the probably, really the problem now in Italy. I have had many experience in PPPs, public private partnerships in building infrastructures. Even I have a background in biology. I did a job in managing large infrastructures buildings such as the last metropolitana, last underground line here in Milan and in a couple of highways. And I had very bad nights in managing this coupling of public mentality on one side and the private attitude. And of course we should do much better in this thing. I think the first problem is that and I would like to work on it. The first problem is cultural attitude because in the public institutions and the public mindset doesn't look very well with empathy towards profit and there is a bad vision. I don't know if, you know, is a heritage of an Italian, I don't know if it's Italian because in our long history we had even very good tradition in doing entrepreneurship. But in last years we are looking, we have suspicion to some initiative. First of all, work on cultural attitude. I think that this meeting has been done even for motivating and inspiring young researchers to look in a different way at entrepreneurial opportunities because it's better to stay in the labs but also look at possible outcomes even not only in terms of money. I would like to mind about technology transfer and the valorization of science like a get back for society. And that's it. This is my main concern. About the specific regulation I think you are much more expert than me, you know, I'm sure. And what I would like, what I can do is that having a governmental mandate we are very open to collect requests by private and public experts working in the field to reinforce because I'm sure they know what should be done but they don't do it. I'm speaking about regulators. I don't want to get around. If we look at what has been the discussion about the end of life in the euthanasia, that specific issue where even the constitutional court said to the politicians you have to rule this domain. Nothing has been done. So we should get back and we should reinforce our questions available to do so and we can ask even to Marco Simoni that chairman of human technology and much more authoritative than me. I would like to ask, I don't know if I can take the floor. Even because we have a few minutes of time if we can ask to the people here to present themselves and to say some words why they ask to take part to this meeting. May I? Can we start from... No, Juju, because he's not ready. Thanks so much. Francesco Barcotti, I would like to present myself together with my two colleagues behind me that are Cosmin Narazu and Giuseppe Guagliano. Where are you from? We are from Amics, I would say, Milan, Turin and Pavia. And basically we are here because we are working with a patented nanotechnology Mjuka's similar nanotechnology for drug delivery and personally I'm both in this, let's say, entrepreneur award and in big pharma award but my colleagues behind me are currently doing their actual research on that technology. Thank you. That's the reason I asked the question before this. Let's do it. I'm Bianco Berzeghini, I'm a PhD student in bioengineering at Politecnico di Milano and we focus our research on translation medicine with the scaffold that are 3D structure for stem cell therapies. So we are here because we participate to switch to product competition in Politecnico and I'm pleased to be here for this. Thank you all for your intervention. Thank you. I'm Cristiano Bertini and I'm a PhD student in bioinformatics. I'm here for many reasons that mostly for curiosity about this kind of field. I have some ideas in mind. I'm in my last year of PhD so I'm even wondering what I will do and I will be hold. So that's a good point to start and getting an idea, continue to the academia, moving between academia and not academia worked. Having a real job and it could be something that could be interesting for me. So I really enjoyed this this talk. I didn't participate so much with questions and so on. I'm just like a little wonder. We are new but yeah I was really interested in the speech and I have some ideas in mind with my work. So give me some inspiration. Thank you. I'm Mark Bizzocchi and I'm here with my colleague of mine, Silvia. We are from Humanitas University and we are just here for curiosity because we want to understand the technology transfer you are students we are postdoc We just got our PhD last year so we were since for me I'm not I don't know much about these topics and some things so I think it's good to also because we do basic research we are neuroscientists and it's good to know basic research to go to the market and to really help people not just doing research but also answer the question and resolve the problems so it was every talks were very interesting and inspiring so thank you very much for having us. You like. Hi everyone, I'm Andrea Crosino I'm a PhD student in plant biotechnology my research is focused on the production on molecules in order to bio stimulates plant growth and production and I'm here because I needed new motivations because I'm a bit in trouble with my research Did you get it? Yeah, a lot, a lot. Thank you very much. I'm Roberta Nossa I am biomedical engineering I got my PhD like 2 years ago and now I'm a researcher at ERX media in LECCO but in the future probably I should work in the technology transfer office but at the moment I know almost nothing and so I'm trying to catch where I can some notions and so that's the reason I'm here. Thank you Needed To see if I can open a startup or I have funding to go further and see if this molecule can be effective in the future. Let us know something about it. Yeah sure, I would like to discuss with you and with Dr. Saffacio. If you have 5 minutes of your time to dedicate, thank you. Thank you. My name is Marta Bortoletto I work at the ERX in Fratelli in Brescia and I'm the lab leader of the neurophysiology lab. I'm here because I've been given the task to understand better technological transfer and also because we use a lot of medical devices and sometimes we have the view of the clinician or the application and we kind of like want to integrate our need with the people that develop the technology but yeah so I came here because I really wanted to understand better all the different stakeholders, all the different entities that are involved in the process. And did you get the point? I did, I did, I learned a lot that was very good still I have lots of questions but that was a great start. Thank you. When is this in? Davide Ederle from Abinovacena Trentino we are in charge of technology transfer initiatives to research foundation and University of Trento. So I'm here just to make some networking and know each other and share experiences and opportunities of collaboration. Thank you. Thank you so much. We shall conclude this. Please, please. Go ahead. Hi, Ilaria Corridori from the University of Trento. I'm a postdoc at the department of industrial engineering and I'm here both for two reasons. The first one is that I'm working on a possible spin-off at biotec center of biotechnologies under the department of industrial engineering at the University of Trento and also because I'm very interested in the technology transfer issues and so I came here. Thank you. Hi. I am Karina Kujokarum and I'm doing the PhD at the University of Torino. Actually I'm working at Pancreatic Cancer. It has nothing to do with the subject of this workshop but I was curious and I still don't know what I want to do after the PhD so I'm trying to see what's in the work. It has a lot to do with not having. I'm doing basic research so it's very far from the translational one. I think it's a very hot issue for me. I'm Karina Tertulli from Rome in the University of Cataliga del Sacro Cuore and the resident in Newmology there. I'm here because I found myself these days a bit tired in the classical clinician figure so I was I wanted to becoming something more and applying my knowledge in a more research kind of job. I had a really great ideas and it was really a pleasure participating in this workshop. Thank you very much. I take the chance to say that you will be distributed in future a sort of a question to the present people and to the people following us online about pros and cons and comments on this initiative and suggestions and wishes for future initiatives so you can do it. I'm Elena Zarbini I'm a PhD student from the University of Insubria. I'm here for curiosity because I'm started to looking for the view of doing research and doing an alternative in future. Okay. Thank you. Hi, I'm Filippo Molinari. I'm from the University of Insubria too. I work on lignin valorization in particular on enzymatic biocatalysis and since after the PhD I could be working in industry I want to know something about patent regulation and other field in academia. Thank you for your folks. Thank you to you. Good afternoon everybody. John Luca Turco, associate professor of the University of Trieste and also the delegate of the medical department in technology transfer and I have to say that I am also the co-inventor of two patents and co-founder of startup which started and were great for me because I saw a lot of things that I did wrong in the past. Sorry, that may be to not do them again in the future and it was really great to be here with you. Thank you very much. Trieste is a very important site for science. Good afternoon. I'm Antonila Potensan and I'm here with my colleagues. We came from anemologica to institut of Vesta, Yuri Milen. We are key on cerebrovascular disease studies and we came here just because we were interested and curious about TUT in this application. Thank you. I hope we can work in the future very in the next few months with Vesta too or so. My name is Fernanda Pinheiro. I am a group leader in computational biology here at Human Technopole. My research is focused on building mathematical models to predict the evolution of antibiotic resistance. So I'm here because I'm curious about technology transfer. I think it's something that we don't have in our formation in academia. Like I'm a physicist, I have never been exposed to such things. And also because in the context of my research I think this is a challenge with antibiotics so I wanted to understand from the viewpoint of industry. How is it that academia could contribute to the problem that we're going to face in the next year. Thank you for taking part for such a meeting. Thank you for organizing. So hi to everybody, I'm Luitia Pache. I'm Pihai at IGM Candiolo Cancer Research Institute close by Turin. So I'm immunologist, I'm interested in epigenetic targets that initiate the memory mirror responses. During my postdoc five years ago, I patented one of these epigenetic targets that been financed last year with 75 millions of dollars, so first class start-up. Now we have new targets now I'm working in Italy and I would like to know how to move further with the protection of the patent and also how to see how the country can support our idea. So you meet here, played your expert so you can ask directly to him. In fact, when I was postdoc so I was one of the pioneer with my PI on introducing the concept of epigenetic targets to modulate specific enzymes in heterochromatin factors that are compacting the nucleus so activating and shutdown genes. So it was very well financed but then I left in Paris the patent, but now we have new targets here in Italy and I don't know how to move further. Ok, just the last two Yeah, yeah, it's always well done. My name is Luigi Cristiano and I introduce also my colleague Anelangelo. We are a search fellow at the USPAVIA and we are doing research in technology transfer and research civilization so our goal is to help researcher to create patent and protect your ideas. Thank you. I think this tool has been very heterogeneous but for me it's a satisfaction to listen to some of your stories and possible collaboration with all the people that's here. Before leaving the floor back to Ricardo I stole the microphone. Sorry about that. I want to thank first of all Marika Nobile that together with Valeria Tardano and Bianca Montini they and all the people working their technical staff thank you very much because it's not so easy to manage such a digital event it's sort of a TV broadcast and together a live event and so on but we should be used to do so. Thank you again and I go away. Thank you. Ricardo. Thank you.